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NeuroimagingThe recently discovered hexanucleotide repeat expansion, C9ORF72, has been shown to be among the most
common cause of familial behavioural variant frontotemporal dementia (bvFTD) and to be present in a sig-
niﬁcant minority of apparently sporadic cases. While mounting evidence points to prominent episodic mem-
ory dysfunction in bvFTD cases, recent reports have also suggested an amnestic proﬁle in C9ORF72 mutation
carriers. No study to date, however, has formally characterised the extent to which episodic memory is im-
paired in C9ORF72 mutation versus sporadic cases, or the underlying neural substrates of such deﬁcits. We
conducted a comparison of C9ORF72 (n = 8) and sporadic (n = 15) bvFTD cases using a battery of verbal
and visual episodic memory tasks, and contrasted their performance with that of Alzheimer's disease (AD,
n = 15) and healthy older control (n = 15) participants. Behaviourally, the two bvFTD groups displayed
comparable episodic memory proﬁles, irrespective of task administered, with prominent impairments evi-
dent relative to Controls. Whole-brain voxel-based morphometry analyses revealed distinct neural correlates
of episodic memory dysfunction in each patient group. Widespread atrophy in medial prefrontal, medial and
lateral temporal cortices correlated robustly with episodic memory dysfunction in sporadic bvFTD cases. In
contrast, atrophy in a distributed set of regions in the frontal, temporal, and parietal lobes including the pos-
terior cingulate cortex, was implicated in episodic memory dysfunction in C9ORF72 cases. Our results demon-
strate that while episodic memory is disrupted to the same extent irrespective of genetic predisposition in
bvFTD, distinct neural changes speciﬁc to each patient group are evident. The involvement of medial and lat-
eral parietal regions in episodic memory dysfunction in C9ORF72 cases is of particular signiﬁcance and repre-
sents an avenue of considerable interest for future studies.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Frontotemporal dementia (FTD) refers to a progressive neurodegen-
erative disorder which accounts for a signiﬁcant proportion of young
onset dementia (Ratnavalli et al., 2002), and is characterised by clinical
and pathological heterogeneity. Patients with the behavioural variant
of FTD (bvFTD) present with ﬂorid changes in behaviour and interper-
sonal functioning, manifesting in reduced motivation and disinhibition
(Piguet et al., 2011), which is associated with prefrontal, insular andtralia, Randwick, Sydney, NSW
nc. Open access under CC BY-NC-ND litemporal cortical degeneration (Rabinovici et al., 2007; Seeley et al.,
2008). The recently discovered hexanucleotide repeat expansion in the
C9ORF72 gene has been shown to be among the most common causes
of familial FTD (Boeve et al., 2012; DeJesus-Hernandez et al., 2011;
Mahoney et al., 2012a; Simon-Sanchez et al., 2012) and motor neurone
disease (MND) (Byrne et al., 2012; Chio et al., 2012; Cooper-Knock et al.,
2012; Renton et al., 2011). Importantly, the mutation has also been
found in around 2–4% of FTD cases with no apparent family history
(DeJesus-Hernandez et al., 2011; Mahoney et al., 2012a; Simon-
Sanchez et al., 2012). Not surprisingly, current research efforts are fo-
cused on discriminating C9ORF72 mutation carriers from non-carriers
in vivo at the earliest disease stage.
On a clinical level, demographic features, such as age of onset, sex, and
disease duration at presentation, do not seem to differentiate between
carriers and non-carriers of the mutation, however, a number of distinc-
tive clinical features have been observed in C9ORF72 mutation-positivecense.
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compared to sporadic cases (Boeve et al., 2012; Sha et al., 2012;
Snowden et al., 2012). In addition, a high proportion of C9ORF72 cases
have been reported to display features of ALS (Boeve et al., 2012;
Hsiung et al., 2012; Mahoney et al., 2012a; Sha et al., 2012; Simon-
Sanchez et al., 2012; Snowden et al., 2012), which is in keeping with
the observation of a family history ofmotor neuronedisease in this cohort
(Snowden et al., 2012). Evidence of Parkinsonism has also been reported,
giving rise to a mild akinetic syndrome without the presence of tremor
(Boeve et al., 2012; Hsiung et al., 2012; Sha et al., 2012; Simon-Sanchez
et al., 2012; Snowden et al., 2012).
Of particular interest in this context is the observation of severe an-
terograde amnesia in C9ORF72 cases, leading to potential misdiagnosis
as Alzheimer's disease (Dobson-Stone et al., 2012; Mahoney et al.,
2012a; van Swieten and Grossman, 2012). Accordingly, the nature of
episodic memory impairment represents an important line of enquiry
for determining which patients should be considered candidates for
screening for C9ORF72 expansions (van Swieten and Grossman, 2012).
Evidence regarding the extent to which episodic memory processes
are compromised in C9ORF72 mutation cases is limited. While signiﬁ-
cant episodic memory impairment was a prominent feature of the
C9ORF72 case series reported from London (Mahoney et al., 2012a),
this observation was made on the basis of a retrospective analysis of
case notes. In fact, the majority of studies reporting on the clinical char-
acteristics of C9ORF72 cases hinge on retrospective clinical case note re-
views, which likely underestimate the rate and extent of cognitive
dysfunction (Hodges, 2012).
The present study therefore sought to formally characterise the ex-
tent to which episodic memory is disrupted in C9ORF72 in comparison
with sporadic bvFTD cases by (i) conducting an analysis of C9ORF72
and sporadic bvFTD cases who were all assessed prospectively using a
battery of verbal and visual episodic memory tasks, and (ii) exploring
the neuroanatomical contributions to these episodic memory impair-
ments using whole-brain voxel-based morphometry analyses based
on structural scans. We hypothesised that C9ORF72 and sporadic
bvFTD cases would show largely similar behavioural proﬁles of episodic
memory dysfunction, in keeping with previous reports in the literature
(Dobson-Stone et al., 2012; Mahoney et al., 2012a; van Swieten and
Grossman, 2012), with both patient groups displaying prominent
memory deﬁcits relative to Controls. Given recent evidence which
points to a possible neuroanatomical signature of the C9ORF72mutation
(Whitwell et al., 2012), we predicted that distinct neural correlates
would underpin episodic memory dysfunction contingent on bvFTD
subgroup. Speciﬁcally, we hypothesised that the origin of episodic
memory dysfunction in sporadic bvFTD cases would stem from atrophy
overwhelmingly in medial prefrontal and anterior temporal regions, in
line with previous studies (Frisch et al., 2013; Irish et al., 2013;
Pennington et al., 2011). In contrast, for C9ORF72 cases, we predicted
that episodic memory deﬁcits would relate to atrophy in frontal, lateral
temporal, and parietal regions, given recent evidence of extensive pari-
etal atrophy in this cohort (Sha et al., 2012).
2. Methods
2.1. Participants
A total of 53 subjects participated in this study: 8 behavioural variant
frontotemporal dementia (bvFTD) cases identiﬁed as C9ORF72 muta-
tion carriers (referred to as C9 cases), 15 bvFTD cases who lack muta-
tions in C9ORF72 (sporadic bvFTD), 15 cases with Alzheimer's disease
(AD), and 15 age-matched healthy Controls, all selected from the
FRONTIER database, at Neuroscience Research Australia, Sydney. All de-
mentia patients met clinical diagnostic criteria for bvFTD (Rascovsky et
al., 2011) or AD (McKhann et al., 2011), with 2 of the C9 cases showing
FTD-MND features with disease progression (Strong et al., 2009).With-
in the C9 group, 3 patients had a family history of MND, 2 patients had afamily history of early-onset dementia, and 1 patient had a family histo-
ry of Parkinson's disease. For sporadic bvFTD cases, 3 patients were
found to have a family history of early-onset dementia, with no family
history of MND or Parkinsonism evident in any of the sporadic cases.
Blood collection for genetic screening had been conducted during a
previous clinical visit, following informed consent. The repeat primed
polymerase chain reaction (PCR) was performed using the procedure
described previously (Dobson-Stone et al., 2012), based on the protocol
of Renton and colleagues (Renton et al., 2011). A patient's DNA sample
was deemed positive for the C9ORF72 repeat expansion if it contained
an allele with N30 repeats. All bvFTD patients were screened for other
common genetic mutations (GRN, MAPT), however, no positive cases
were identiﬁed.
Diagnosis was established by consensus among a senior neurolo-
gist (JRH), neuropsychologist, and occupational therapist based on
clinical investigations, cognitive assessment, carer interviews, and ev-
idence of atrophy on structural neuroimaging. Brieﬂy, bvFTD patients
presented with insidious onset, decline in personal conduct and social
functioning, displaying emotional blunting, loss of insight, and in-
creased apathy. Only dementia patients with evidence of deﬁnite pro-
gression over time as reported by the caregivers, and atrophy on
structural MRI scans were included in this study. This was to exclude
potential phenocopy cases in the FTD group (Kipps et al., 2010) and to
conﬁrm the diagnosis for all cases. AD patients displayed signiﬁcant
episodic memory loss, in the context of preserved behaviour and
personality.
Healthy Controls were patients' family and friends, and individuals
from local community clubs. All Controls scored 0 on the Clinical De-
mentia Rating scale (CDR) (Morris, 1997), and 88 or above on the
Addenbrooke's Cognitive Examination — Revised (ACE-R) (Mioshi et
al., 2006). Exclusion criteria included prior history of mental illness, sig-
niﬁcant head injury, movement disorders, cerebrovascular disease, al-
cohol and other drug abuse, and limited English proﬁciency. Ethical
approval for this study was obtained from the South Eastern Sydney
and Illawarra Area Health Service and the University of New South
Wales ethics committees. All participants, or their person responsible,
provided informed written consent in accordance with the Declaration
of Helsinki.
2.2. General cognitive testing
All participants completed a comprehensive neuropsychological test
battery as part of their diagnostic work-up. Brieﬂy, global cognitive
functioning was assessed using Addenbrooke's Cognitive Examination
Revised (ACE-R) (Mioshi et al., 2006), which comprises subscales
measuring attention and orientation, memory, ﬂuency, language and
visuospatial functioning. The Trail Making Test (Reitan, 1958), was ad-
ministered to all participants as an index of attention, speed, andmental
ﬂexibility. Here, we were interested in set-switching and divided atten-
tion and thus used a Trail B − Trail A difference score (Strauss et al.,
2006). Verbal letter ﬂuency (F, A, S) (Strauss et al., 2006) was adminis-
tered as an index of strategic search processes, and Digit span forwards
and backwards tasks of theWechslerMemory Scale (WMS3) (Wechsler,
1997) were used as indices of verbal working memory. Finally, the
Hayling test (Burgess and Shallice, 1997) was used to assess behavioural
regulation, speciﬁcally response inhibition (Strauss et al., 2006). Carers
rated the behavioural changes of patients on the Cambridge Behavioural
Inventory (CBI) (Wedderburn et al., 2008), in terms of memory decline,
and loss of motivation.
2.3. Episodic memory testing
The procedure for this study has been described in detail else-
where (Irish et al., 2013). Brieﬂy, we administered a battery of verbal
and visual episodic memory tests to all participants. The Rey Auditory
Verbal Learning Test (RAVLT) (Schmidt, 1996) was used to assess the
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trials. Each trial is followed by a free recall test. An interference trial
comprising 15 new words (List B) and a free recall test is then
presented, following which, the participant is required to retrieve
words from the original List A (immediate recall). Following a
30-minute delay, the participant is required to recall List A (delayed
recall). We extracted the following scores from the RAVLT: immedi-
ate recall following the interference trial (maximum score: 15) and
delayed recall following 30 min (maximum score: 15).
The Rey-Osterrieth Complex Figure (RCF) (Meyers andMeyers, 1995)
was administered as an index of visual recall of a complex design follow-
ing a 3-minute delay. Participants were instructed to copy a complex ﬁg-
ure as accurately as possible and, following the delay, were required to
reproduce the ﬁgure from memory. The maximum score for both the
copy and recall trials is 36 points. For all experimental scores, a percent-
age correct score was calculated (i.e., raw score/total test score ∗ 100).
2.4. Statistical analyses
Cognitive data were analysed using IBM SPSS Statistics (Version
20.0). Multivariate analyses of variance (MANOVA) with Sidak post
hoc tests were used to explore main effects of group (Controls, C9,
sporadic bvFTD, AD) for all episodic memory tests. The rationale for
using Sidak modiﬁcation of the traditional Bonferroni post hoc test
is that the statistical power of the analyses is not affected, while the
ﬂexibility of the original Bonferroni method is maintained (Keppel
and Wickens, 2004). Chi-squared tests (χ2), based on the frequency
patterns of dichotomous variables, were also used. To investigate re-
lationships between patterns of grey matter intensity and episodic
memory performance, all experimental scores (RAVLT Immediate
Recall, RAVLT delayed recall, RCF recall) were entered into a single
design matrix as covariates in the neuroimaging analyses.
2.5. Image acquisition
Voxel-based morphometry (VBM) was used to identify grey matter
intensity changes across groups on a voxel-by-voxel basis using struc-
turalMRI data. Participants underwent whole-brain T1-weighted imag-
ing using a 3 T Philips MRI scanner with standard quadrature head coil
(8 channels), using the following sequences: coronal orientation,matrix
256 × 256, 200 slices, 1 × 1 mm2 in-plane resolution, slice thickness
1 mm, echo time/repetition time = 2.6/5.8 ms, ﬂip angle ɑ =19°. MRI
data were analysed with FSL-VBM, a voxel-basedmorphometry analysis
(Ashburner and Friston, 2000; Mechelli et al., 2005) using the FSL-VBM
toolbox from the FMRIB software package (http://www.fmrib.ox.ac.uk/
fsl/fslvbm/index.html) (Smith et al., 2004). Brieﬂy, structural images
were extracted using the brain extraction tool (BET) (Smith, 2002).
Tissue segmentation was then carried out on the brain extracted images
using FMRIB's Automatic Segmentation Tool (FAST) (Zhang et al., 2001).
The resulting grey matter partial volumes were then aligned to the
Montreal Neurological Institute standard space (MNI152) using the
FMRIB non-linear registration approach (FNIRT) (Andersson et al.,
2007a, 2007b), which uses a b-spline representation of the registration
warp ﬁeld (Rueckert et al., 1999). A study-speciﬁc template was creat-
ed, combining AD, C9, sporadic bvFTD, and Control images, to which
the native grey matter images were re-registered nonlinearly. The reg-
istered partial volume maps were then modulated by dividing by the
Jacobian of the warp ﬁeld. This step was carried out to correct for local
expansion or contraction. The modulated segmented images were
then smoothedwith an isotropic Gaussian kernelwith a sigma of 3 mm.
2.6. Voxel-based morphometry analysis
A voxel-wise general linear model was applied to investigate grey
matter intensity differences via permutation-based non-parametric
testing (Nichols and Holmes, 2002) with 5000 permutations percontrast. In a ﬁrst step, differences in cortical greymatter intensities be-
tween each patient group (C9, sporadic bvFTD, and AD) and Controls
were assessed. Next, correlations between performance on experimen-
tal episodic memory tests and regions of grey matter atrophy were in-
vestigated in each of the patient groups contrasted with controls. This
procedure serves to increase the statistical power to detect brain–
behaviour relationships across the entire brain by achieving greater var-
iance in behavioural scores (see Irish et al., 2012a; Sollberger et al.,
2009). For statistical power, a covariate only statistical model with a
[1] contrast was used, providing an index of association between grey
matter intensity and episodic memory. In line with a previous study
by our group (Irish et al., 2013), the three episodic memory task scores
were included separately in themodel, and educationwas included as a
covariate in all analyses given the difference between Controls and C9
patients (see below). Anatomical locations of signiﬁcant results were
overlaid on theMNI standard brain,withmaximumcoordinates provid-
ed in MNI stereotaxic space. Anatomical labels were determined with
reference to the Harvard–Oxford probabilistic cortical atlas.
3. Results
3.1. Demographics
Demographic and clinical information is presented in Table 1. The
participant groups were well matched for age (p = .467) but not for
years in education (F(3, 49) = 4.370, p = .008) as Controls spent on
average 4 years longer in formal education in comparison to the C9
cases (p = .007). Sex was evenly distributed between the participant
groups (p = .843). The patient groups were matched for disease du-
ration (i.e., the number of months elapsed between onset of symp-
toms and cognitive testing, p = .151).
3.2. General cognitive screening
Signiﬁcant group differences were evident for the total ACE-R score
(F(3, 49) = 24.493, p b .0001), with all patient groups scoring signiﬁ-
cantly lower than Controls (all p values b .0001). No signiﬁcant differ-
ences were found between patient groups for total ACE-R score (all p
values N .3). The digit span forwards (F(3, 42) = 4.210, p = .011)
and backwards (F(3, 42) = 9.282, p b .0001) tasks revealed signiﬁcant
group differences. AD patients showed signiﬁcantly poorer forwards
(p = .013) and backwards (p b .0001) digit span in comparison with
Controls. C9 cases displayed a tendency towards compromised for-
wards digit span (p = .060) with clear deﬁcits emerging on the back-
wards span task (p = .004) with respect to Controls. Finally, sporadic
bvFTD cases demonstrated intact forwards span (p = .459) but impair-
ments for backward span (p = .007) in comparison with Controls. No
signiﬁcant differences were observed between the FTD subgroups for
forwards or backwards digit span (all p values N .7).
All patient groups performed signiﬁcantly poorer than Controls on
the Hayling test (F(3, 38) = 11.914, p b .0001; C9 p b .0001; Sporadic
bvFTD p b .0001; AD p = .011). For letter ﬂuency, again, signiﬁcant
impairments were evident in the patient groups relative to Controls
(F(3, 42) = 10.326, p b .0001) with no signiﬁcant differences be-
tween the patient groups (all p values N .7). On the Trail Making
Task, all patients were impaired in comparison with Controls (F(3,
42) = 5.429, p = .003; C9 p = .059; Sporadic bvFTD p = .006; AD
p = .056), again with no signiﬁcant differences between patient groups
evident (all p values N .9). Finally, no signiﬁcant differences were ob-
served between patient groups for caregiver ratings of memory impair-
ment (all p values N .9) or loss ofmotivation (all p values N .1) on the CBI.
3.3. Episodic memory performance
Fig. 1 displays the performance of the patient groups (C9, sporadic
bvFTD, AD) and Controls on each of the episodic memory recall tasks.
Table 1
Demographic and clinical characteristics of study participantsa,b.
C9 Sporadic AD Controls F test C9 vs. Sporadic
N 8 15 15 15
Sex (m: f) 6: 2 9: 6 11: 4 10: 5 n/s n/s
Age (years) 60.4 (4.6) 63.9 (9.3) 64.3 (5.5) 64.6 (4.0) n/s n/s
Education (years) 10.4 (1.8) 12.3 (3.1) 12.1 (2.8) 14.3 (2.2) n/s
Disease duration (months) 61.1 (38.0) 36.5 (21.9) 42.2 (26.1) n/a n/s n/s
ACE-R total (100) 78.5 (8.2) 78.5 (9.1) 73.3 (8.8) 95.9 (3.5) ⁎⁎⁎ n/s
Trails (B–A in s) 121.6 (71.4) 145.5 (98.5) 119.2 (72.5) 39.9 (23.9) ⁎⁎
Letter ﬂuency 23.2 (9.8) 23.3 (10.4) 29.3 (13.3) 47.2 (11.3) ⁎⁎⁎
Digit span forwards 8.1 (1.8) 9.7 (1.8) 8.2 (2.8) 11.5 (2.5) ⁎ n/s
Digit span backwards 4.7 (1.6) 5.2 (2.5) 4.4 (1.8) 8.5 (2.4) ⁎⁎⁎ n/s
Hayling
Scaled score
3.1 (1.8) 2.9 (2.1) 3.8 (1.9) 6.5 (0.6) ⁎⁎⁎ n/s
CBI Memory (100) 38.7 (24.4) 41.2 (22.6) 40.6 (22.8) n/a n/s n/s
CBI Motivation (100) 41.2 (36.0) 58.6 (36.4) 25.7 (25.8) n/a n/s n/s
CBI information available for 14 Sporadic cases. Hayling data available for 14 Sporadic cases. Digit span data available for 7 C9 and 12 Sporadic cases.
a Standard deviations in brackets, maximum score for tests shown in brackets.
b Trail Making test data for 11 Sporadic and 9 AD cases.
⁎ p b .05.
⁎⁎ p b .005.
⁎⁎⁎ p b .0001.
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cluded as a covariate, revealed a main effect of group for immediate
and delayed recall on the RAVLT (Immediate, F(3, 47) = 19.552,
p b .0001; Delayed, F(3, 47) = 21.797, p b .0001). Sidak post hoc
tests revealed Controls signiﬁcantly outperformed patient groups for
Immediate (C9, p = .011; Sporadic, p b .0001; AD, p b .0001) and
Delayed (C9, p = .004; Sporadic, p b .0001; AD, p b .0001) recall. Im-
portantly, no signiﬁcant differences were evident among the patient
groups for any of the RAVLT subscales (all p values N .1).
Further, a main effect was found for RCF recall (F(3, 47) = 9.660,
p b .0001). Sidak post hoc tests revealed that while Controls performed
signiﬁcantly higher than Sporadic (p = .002) and AD (p b .0001)
patients, no signiﬁcant difference was evident between Controls and
C9 patients on this task (p = .105). Finally, no signiﬁcant differences
were observed between the patient groups (all p values N .5).Fig. 1. Barchart showing percentage correct scores for C9 mutation carriers, sporadic be-
havioural variant FTD and Alzheimer's disease participants in comparison with healthy
Controls on each of the episodic memory tasks. Error bars represent standard error of
the mean.3.4. Voxel-based morphometry results
3.4.1. Patterns of atrophy in study samples
Fig. 2 displays the patterns of atrophy in C9, Sporadic, and AD
patients in comparison to healthy Control participants, corrected for
Family Wise Error (FWE) multiple comparisons at p b .05. The C9Fig. 2. Voxel-based morphometry analyses showing brain areas of decreased grey
matter intensity corrected for Family-Wise Error at p b .05 in (A) C9 mutation carriers
in comparison with Controls (blue), (B) sporadic bvFTD patients in comparison with
Controls (red), and (C) Alzheimer's disease patients in comparison with Controls
(green). Coloured voxels show regions that were signiﬁcant in the analysis using the
threshold-free cluster enhancement method (tfce), and overlaid on the MNI standard
brain. All clusters reported t N 2.07.
Fig. 3. Voxel-based morphometry analyses showing brain regions in which grey matter
intensity correlates signiﬁcantly with episodic recall performance in (A) C9 mutation
carriers in comparison with Controls (blue), (B) sporadic bvFTD patients compared
with Controls (red), and (C) Alzheimer's disease patients in comparison with Controls
(green). Coloured voxels show regions that were signiﬁcant in the analysis with
p b .001 uncorrected for sporadic bvFTD and AD contrasts, and p b .01 for C9 contrasts.
All clusters reported t N 2.82. Clusters are overlaid on the MNI standard brain.
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frontal, temporal and parietal cortices, bilaterally (Fig. 2A). Notably
the regions affected included the frontal poles and orbitofrontal cortices
bilaterally, extending into the temporal poles, and medial temporal
structures including the amygdala, hippocampus and the thalamus bi-
laterally. Atrophywas also pronounced in the precentral gyrus bilateral-
ly, the parietal opercular cortex and superior parietal lobule bilaterally,
the posterior cingulate cortex bilaterally, and the bilateral occipital
poles. These patterns of atrophy largely replicate those reported previ-
ously (Sha et al., 2012; Whitwell et al., 2012), although we did not
ﬁnd evidence of cerebellar atrophy in our C9 mutation group as has
been noted in previous studies (Mahoney et al., 2012a; Sha et al.,
2012; Whitwell et al., 2012).
In contrast, the sporadic bvFTD group showed striking and wide-
spread bilateral atrophy, more extensive on the right hand side, ema-
nating from the medial prefrontal cortices to encompass the temporal
pole, insular cortex, OFC, anterior cingulate cortex, and frontal poles
bilaterally. Marked atrophy was also evident in the cerebellum, lateral
temporal, and occipital lobes, as well as in subcortical structures in-
cluding the hippocampus, amygdala, thalamus, and caudate, bilateral-
ly (Fig. 2B).
Finally, AD patients showed widespread atrophy, compared to Con-
trols, in medial temporal regions including the bilateral hippocampii
and amygdalae, extending into bilateral frontal, temporal and parietal re-
gions, and extending posteriorly into the lateral occipital cortices. Further
atrophy was evident in the right lateral temporal cortices (Fig. 2C).
Direct comparisons between the C9 and sporadic bvFTD cases re-
vealed that sporadic cases showed signiﬁcantly more atrophy in the
cerebellum bilaterally, as well as in medial temporal regions includ-
ing the right hippocampus, right amygdala, and right temporal pole.
Further, sporadic cases showed signiﬁcantly more atrophy in the
right paracingulate and anterior cingulate gyri and the right lateral
occipital cortex (p b .05). Given the small C9 sample, and the ensuing
reduced detection power, we used a less conservative threshold to in-
vestigate the reverse contrast (C9 versus Sporadic). This contrast
failed to reveal any signiﬁcant regions of greater atrophy in the C9
group compared with the sporadic group (p b .01, uncorrected).
3.4.2. Neural correlates of episodic memory performance
Fig. 3 shows the brain regions associated with episodic memory
performance in C9 (A), Sporadic (B) and AD (C) cases. Given the
smaller sample of C9 patients, and the ensuing reduction in detection
power, we lowered the cluster height threshold for our analyses
(p b .01 uncorrected) to explore the neural substrates of recall dysfunc-
tion in this group. Recall performance in C9 patients was associated
with grey matter intensity decrease in a distributed set of frontal, and
temporal, regions including the bilateral temporal cortices extending
to the bilateral parahippocampal cortices and notably the right posteri-
or hippocampus. Importantly, a distinct set of parietal regions were im-
plicated in episodic memory dysfunction in the C9 group including the
bilateral superior parietal lobule, the right supramarginal gyrus and
right precuneus, and the bilateral posterior cingulate cortices (Fig. 3A,
Table 2).
In contrast, for sporadic FTD cases, recall performance correlated ex-
tensively with right medial prefrontal and bilateral orbitofrontal cortices
extending to the right insular cortex. Lateral andmedial temporal regions
were also implicated, including the temporal poles bilaterally, the hippo-
campus and amygdala bilaterally, as well as bilateral cerebellum, left pa-
rietal operculum cortex, and left lateral occipital cortex (Fig. 3B, Table 3).
Finally for AD cases, recall performance was associated with a dis-
tributed set of frontal, temporal and parietal regions including the bilat-
eral precuneus, bilateral lateral temporal cortices, left hippocampus,
bilateral frontal poles, aswell as the bilateral angular gyrus and bilateral
occipital cortices (Fig. 3C, Inline Supplementary Table S1).
Inline Supplementary Table S1 can be found online at http://dx.
doi.org/10.1016/j.nicl.2013.06.005.4. Discussion
The recent discovery of the C9ORF72 repeat expansion has led to a
surge of research seeking to establish clinical hallmark features of cases
with this mutation, with an amnestic proﬁle proposed as a potentially
distinguishing feature of this syndrome. The goal of this study was to
characterise the extent to which episodic memory is compromised in
C9ORF72 bvFTD cases and to elucidate the neural correlates of episodic
memory dysfunction in this group. Behaviourally, C9ORF72 cases showed
substantial episodic memory impairments relative to age-matched
Controls, scoring at similar levels to sporadic bvFTD and AD participants.
Notably, a distinctive neuroanatomical signature of memory disruption
in C9ORF72 cases was found, involving frontal and lateral temporal, as
well as lateral and medial parietal regions. Our ﬁndings point to impor-
tant differences in terms of the underlying regions implicated in episodic
memory dysfunction in patients with and without the C9ORF72 muta-
tion, despite behaviourally indistinguishable memory proﬁles.
Converging evidence points to the existence of marked episodic
memory dysfunction in the behavioural variant of frontotemporal de-
mentia, attributable to widespread degeneration of the medial prefron-
tal, and anterior lateral temporal cortices (Hornberger et al., 2010, 2012;
Irish et al., 2013; Pennington et al., 2011). Studies investigating the clin-
ical proﬁle of C9ORF72 mutation carriers have suggested that an
amnestic proﬁle represents a characteristic feature of this FTD subgroup
(Dobson-Stone et al., 2012; Mahoney et al., 2012a; van Swieten and
Grossman, 2012), particularly with disease progression (Mahoney et
al., 2012b). Importantly, our current ﬁndings resonate well with the
position that severe episodic memory deﬁcits are present in C9 cases,
however, it is unlikely that C9 mutation carriers can be differentiated
from sporadic cases on the basis of episodic memory proﬁles alone.
Table 2
Voxel-based morphometry results showing regions of signiﬁcant grey matter intensity decrease that covary with episodic memory recall performance for C9 patients contrasted
with Controls.
Regions Hemisphere MNI coordinates Number of voxels
x y z
Temporal fusiform cortex, parahippocampal cortex, inferior temporal gyrus Left −30 −12 −42 805
Parietal operculum cortex, superior parietal lobule Left −46 −40 32 640
Temporal fusiform cortex, parahippocampal cortex, hippocampus Right 34 −2 −50 637
Orbitofrontal cortex, inferior frontal gyrus Left −48 30 −12 550
Supramarginal gyrus, superior parietal lobule Right 42 −30 34 495
Inferior temporal gyrus Right 58 −40 −26 384
Middle temporal gyrus Left −50 −18 −16 301
Supracalcarine cortex, precuneus Right 18 −70 16 286
Precentral gyrus Left −22 −28 52 250
Temporal pole Left −28 18 −30 236
Frontal pole Right 18 48 −10 204
Middle frontal gyrus Left −38 10 54 179
Superior temporal gyrus Right 46 −32 8 177
Insular cortex Left −26 12 14 175
Frontal operculum cortex Right 36 22 14 169
Temporal pole Right 52 24 −18 147
Frontal pole Left −16 52 −10 143
Posterior cingulate cortex Bilateral −2 −18 44 124
Postcentral gyrus Right 18 −38 50 122
Orbitofrontal cortex Left −10 32 −22 122
Occipital pole Right 20 −104 −8 104
All results uncorrected at p b .01; for brevity only clusters with at least 100 contiguous voxels are reported here. Education is included as a covariate in all contrasts. All clusters
reported t N 2.82.
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radic bvFTD cases using our episodic memory battery, despite the sug-
gestion that non-verbal memory might be somewhat less affected in
C9 cases, who scored in line with Controls for recall of a complex ﬁgure.
Itmay be that visual and verbalmemory processes are differentially im-
paired in C9 mutation carriers, and this proposal is certainly worthy of
future investigation.
The most striking ﬁnding to emerge from this study concerns the
neural substrates of episodic memory deﬁcits in the C9 group. Whole-
brain voxel basedmorphometry analyses revealed that atrophy in a dis-
tributed network of frontal, lateral andmedial temporal, and lateral and
medial parietal regions underpinned episodic memory dysfunction in
C9 mutation carriers. Importantly, considerable overlap was observed
between the neural substrates in the C9 groupwith those of the sporad-
ic bvFTD and AD patient groups. Notably, regions commonly implicated
in memory dysfunction in C9 and sporadic bvFTD cases included the
lateral and medial temporal cortices including the right hippocampus,
the right frontal pole, and the bilateral orbitofrontal cortices.Table 3
Voxel-based morphometry results showing regions of signiﬁcant grey matter intensity dec
Controls.
Regions
Frontal pole, medial PFC, anterior cingulate cortex, paracingulate gyrus
Orbitofrontal cortex, inferior frontal gyrus, insular cortex
Temporal fusiform cortex (anterior), parahippocampal gyrus, hippocampus, amygdala
Cerebellum
Temporal pole, orbitofrontal cortex
Parahippocampal gyrus, hippocampus




Precentral gyrus, middle frontal gyrus
Lateral occipital cortex
Middle temporal gyrus
All results uncorrected at p b .001; only clusters with at least 100 contiguous voxels are inclIt is interesting to observe that the neuroanatomical signature of ep-
isodic memory dysfunction in C9 mutation carriers lies somewhat mid-
way on a continuum between the more anterior network commonly
reported in bvFTD and the more posteriorly-oriented substrates of AD
(Frisch et al., 2013; Irish et al., 2013). Perhaps most intriguing is the
ﬁnding of considerable parietal involvement in the C9 group, including
the bilateral precuneal/posterior cingulate cortices, and the bilateral su-
perior parietal lobule, mirroring those observed in the AD group. Exten-
sive lateral andmedial parietal lobe atrophy has been documented in C9
cases, with the suggestion that diffuse parietal atrophy may prove use-
ful in discriminating between carriers and non-carries of the C9ORF72
mutation (Whitwell et al., 2012). Our results mesh well with this asser-
tion, and point to the involvement of parietal regions in the genesis of
episodic memory deﬁcits in C9 mutation carriers. Interestingly, we
found only minimal evidence of cerebellar involvement in episodic
memory impairment in C9 cases (cluster size of 60 contiguous voxels
at p b .01 uncorrected) despite recent suggestions that cerebellar pa-
thology may be a characteristic feature of this group (Whitwell et al.,rease that covary with recall performance for sporadic bvFTD patients compared with
Hemisphere MNI coordinates Number of voxels
x y z
Right 8 38 −30 5012
Right 48 28 −12 1586
Left −30 −6 −52 1028
Right 50 −50 −52 660
Left −38 8 −30 496
Right 28 −22 −34 489
Right 38 −8 −50 469
Left −46 −30 14 355
Left −38 −58 −42 327
Right 48 −30 14 282
Right 44 2 22 261
Left −30 −82 −6 123
Left −70 −30 0 103
uded. Education is included as a covariate in all contrasts. All clusters reported t N 3.40.
842 M. Irish et al. / NeuroImage: Clinical 2 (2013) 836–8432012). In the context of the current sample, lateral and medial parietal
contributions to memory impairment represent a deﬁning feature of
C9ORF72mutation carriers, andmay serve as a usefulmeans of differen-
tiating this cohort from sporadic bvFTD cases.
The integrity of interactions between prefrontal cortical structures
and the medial temporal lobes is pivotal for successful episodic mem-
ory retrieval (Simons and Spiers, 2003). Indeed, our ﬁndings from the
sporadic bvFTD group strongly support this position, given that ex-
tensive atrophy was associated with memory disruption in this pa-
tient group. Our results from the sporadic bvFTD group replicate
previous studies demonstrating that damage to the prefrontal cortex,
and medial temporal lobes, including the hippocampus, are strongly
associated with the amnestic proﬁle in bvFTD (Frisch et al., 2013;
Irish et al., 2013; Pennington et al., 2011). The role of the prefrontal
cortex in episodic memory performance, however, remains compara-
tively poorly understood (Simons and Spiers, 2003). Current evidence
from neuroimaging and lesion studies suggests that strategic aspects
of episodic memory recall are mediated by prefrontal brain structures
(Becker and Lim, 2003; Kramer et al., 2005), in particular the dorso-
lateral prefrontal cortex (Long et al., 2010). Accordingly, it has been
proposed that episodic memory deﬁcits in bvFTD may stem from
compromised strategic retrieval processes due to difﬁculties with
planning and organisation of information during encoding and/or re-
trieval (Kramer et al., 2005; Wicklund et al., 2006). Given the sub-
stantial impairments in executive functioning in bvFTD, emanating
from the progressive deterioration of the frontal lobes (Collette et
al., 2010; Piolino et al., 2007), and the ﬁnding of marked impairments
of bvFTD patients on source memory tasks speciﬁcally stressing pre-
frontal cortical processes (Irish et al., 2012b; Söderlund et al., 2008),
the strategic retrieval hypothesis appears particularly relevant to
memory dysfunction in this group. Importantly, our results lend fur-
ther weight to the proposition that episodic memory dysfunction in
neurodegenerative disorders reﬂects widespread degeneration of
complex neural networks, in which the hippocampus is but one par-
ticipating structure (Irish et al., 2012c; Simons and Spiers, 2003). This
position is underscored by recent ﬁndings from bvFTD patients, in
which speciﬁc nodes of the Papez circuit, including the mammillary
bodies and the anterior thalamus, have been shown to modulate the
amnestic presentation (Hornberger et al., 2012).
Finally, our AD ﬁndings support the large body of evidence in
which a widespread network of medial temporal, frontal, and parietal
structures are implicated in episodic memory dysfunction (Buckner
et al., 2005; Irish et al., 2012a, 2013). Importantly, our behavioural
data reinforce the inherent difﬁculty in distinguishing between clini-
cal AD and FTD patients, but also between C9 and sporadic FTD cases,
based onmeasures of episodic memory alone (Frisch et al., 2013; Irish
et al., 2013). From a clinical perspective, the utility of episodic mem-
ory tests to determine which patients should undergo screening for
genetic mutations does not appear to represent a promising line of
enquiry and we suggest that focusing on the possible neuropsychiat-
ric disturbance in C9 carriers may represent a more fruitful approach.
A number of methodological issues warrant consideration in the
current context. Firstly, our sample of C9 patients who had undergone
structural neuroimaging and memory testing is relatively small, and
limits the extent towhichwe can draw conclusions from these ﬁndings.
That said, it is likely that replication of this study in a larger cohort of C9
cases would reveal interesting group differences, particularly on the vi-
sual memory task. While our neuroimaging analyses on the whole rep-
licated previous reports in the literature, we may have lacked sufﬁcient
power to detect brain–behaviour relationships. Our sporadic bvFTD and
AD patient sample have not yet come to autopsy, and thus we do not
have access to neuropathological data to conﬁrm the disease pathology
in these groups. It is important to note, however, that our ﬁndings con-
verge well with a growing number of studies highlighting severe mem-
ory disruption in pathologically conﬁrmed cases of bvFTD (Graham et
al., 2005; Hornberger et al., 2010, 2012) and in cases with geneticallyconﬁrmed C9ORF72 mutations (Galimberti et al., 2013; Mahoney et
al., 2012b). Replication of our current results in a larger sample, in con-
junction with neuropathological data, represents an important avenue
for future research.
In summary, we have conﬁrmed the presence of marked episodic
memory disturbance in carriers of the C9ORF72 genetic mutation, in
keeping with previous reports in the literature pointing to an amnestic
proﬁle in this group. For C9ORF72 mutation carriers, degeneration of a
distributed set of frontal, lateral and medial temporal, and lateral and
medial parietal regions results in episodic memory deﬁcits, comparable
to that seen in disease-matched sporadic bvFTD and AD cases. Our re-
sults have important clinical implications in that memory impairment
may not represent a useful construct to distinguish between carriers
and non-carriers of the C9ORF72mutation. Given the distinctive neural
substrates underlying episodic memory dysfunction in C9 versus spo-
radic bvFTD cases, we suggest that the next challenge lies in devising
clinically sensitive tools which differentially stress posterior versus an-
terior aspects of episodic retrieval, respectively. This approach may aid
the clinician to identify those candidates who should undergo genetic
screening, with the ultimate goal of creating tailored interventions to
assist in the long-term management of these patients.
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